Hualan Biological Engineering Inc.

SZSE:002007 Stock Report

Market Cap: CN¥29.1b

Hualan Biological Engineering Future Growth

Future criteria checks 3/6

Hualan Biological Engineering is forecast to grow earnings and revenue by 23.6% and 15.8% per annum respectively. EPS is expected to grow by 23% per annum. Return on equity is forecast to be 11.5% in 3 years.

Key information

23.6%

Earnings growth rate

23.00%

EPS growth rate

Biotechs earnings growth42.6%
Revenue growth rate15.8%
Future return on equity11.50%
Analyst coverage

Good

Last updated17 Nov 2025

Recent future growth updates

Hualan Biological Engineering Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 01
Hualan Biological Engineering Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Recent updates

Hualan Biological Engineering Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 01
Hualan Biological Engineering Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Hualan Biological Engineering (SZSE:002007) Seems To Use Debt Quite Sensibly

Feb 27
Hualan Biological Engineering (SZSE:002007) Seems To Use Debt Quite Sensibly

Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Dec 30
Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Hualan Biological Engineering (SZSE:002007) Seems To Use Debt Quite Sensibly

Nov 18
Hualan Biological Engineering (SZSE:002007) Seems To Use Debt Quite Sensibly

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 36% Below Their Intrinsic Value Estimate

Oct 07
Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 36% Below Their Intrinsic Value Estimate

Why Investors Shouldn't Be Surprised By Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Aug 22
Why Investors Shouldn't Be Surprised By Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jun 26
Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate

Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30

Jun 09
Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30

These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely

Jun 07
These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely

Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

May 21
Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Is Hualan Biological Engineering (SZSE:002007) Using Too Much Debt?

Feb 27
Is Hualan Biological Engineering (SZSE:002007) Using Too Much Debt?

Earnings and Revenue Growth Forecasts

SZSE:002007 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20276,1791,663N/A1,5536
12/31/20265,4281,486N/A1,3988
12/31/20254,7551,201N/A1,2596
9/30/20254,2679491,1041,050N/A
6/30/20254,5251,164861969N/A
3/31/20254,4591,1398101,023N/A
12/31/20244,3791,0888041,059N/A
9/30/20244,9201,3384361,113N/A
6/30/20245,4091,395256900N/A
3/31/20245,2491,3923461,027N/A
12/31/20235,3421,4825921,346N/A
9/30/20234,8281,2438071,538N/A
6/30/20233,7531,0201,0991,713N/A
3/31/20234,7571,1948351,268N/A
1/1/20234,5171,076563957N/A
9/30/20224,6771,139136662N/A
6/30/20225,4971,42554704N/A
3/31/20224,4531,2774741,225N/A
1/1/20224,4361,2996211,432N/A
9/30/20215,3111,7091,0161,642N/A
6/30/20214,9251,5599071,594N/A
3/31/20214,9691,6217641,495N/A
12/31/20205,0231,6137041,325N/A
9/30/20204,1341,2846081,166N/A
6/30/20203,6841,2889021,295N/A
3/31/20203,6821,2719531,271N/A
12/31/20193,7001,2831,0901,363N/A
9/30/20193,8191,3441,0881,334N/A
6/30/20193,4181,194N/A1,451N/A
3/31/20193,3511,192N/A1,440N/A
12/31/20183,2171,140N/A1,293N/A
9/30/20182,738961N/A864N/A
6/30/20182,556843N/A590N/A
3/31/20182,392773N/A308N/A
12/31/20172,368821N/A177N/A
9/30/20172,195792N/A146N/A
6/30/20172,091801N/A120N/A
3/31/20172,061843N/A203N/A
12/31/20161,935780N/A330N/A
9/30/20161,767737N/A443N/A
6/30/20161,671690N/A585N/A
3/31/20161,585632N/A549N/A
12/31/20151,472589N/A549N/A
9/30/20151,386575N/A501N/A
6/30/20151,372563N/A429N/A
3/31/20151,263514N/A429N/A
12/31/20141,243538N/A497N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002007's forecast earnings growth (23.6% per year) is above the savings rate (2.6%).

Earnings vs Market: 002007's earnings (23.6% per year) are forecast to grow slower than the CN market (27.6% per year).

High Growth Earnings: 002007's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 002007's revenue (15.8% per year) is forecast to grow faster than the CN market (14.4% per year).

High Growth Revenue: 002007's revenue (15.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 002007's Return on Equity is forecast to be low in 3 years time (11.5%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/19 03:20
End of Day Share Price 2025/11/19 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hualan Biological Engineering Inc. is covered by 24 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ethan CuiBofA Global Research
Fusheng CheungChina Galaxy International Securities (Hong Kong)
Fang QuanChina International Capital Corporation Limited